American College of Clinical Pharmacy
      Search      Cart


NIH Releases New Version of the COVID-19 Treatment Guidelines

March 08, 2023

The COVID-19 Treatment Guidelines Panel (the Panel) has published an updated version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

The prevalence of SARS-CoV-2 Omicron subvariants in the U.S. that are not susceptible to tixagevimab plus cilgavimab (Evusheld) is now more than 90%. Hence, the Panel recommends against the use of tixagevimab plus cilgavimab as COVID-19 PrEP. Several sections of the Guidelines have been revised to reflect this recommendation, including Testing for SARS-CoV-2 Infection, Prevention of SARS-CoV-2 Infection, and many of the sections in Special Populations.

Other sections of the guidelines have also been updated:

  • The Panel updated the information on breakthrough infection in Clinical Spectrum of SARS-CoV-2 Infection and expanded the description of viral or symptom rebound after COVID-19 and prolonged viral shedding with or without symptoms in patients who are immunocompromised and who have COVID-19.
  • Data from 2 case series that describe clinical experience with ritonavir-boosted nirmatrelvir in pregnant patients with COVID-19 has been added to Ritonavir-Boosted Nirmatrelvir (Paxlovid).
  • The Ivermectin section now includes data from 3 large randomized controlled trials. These trials reported that the use of ivermectin did not provide a clinical benefit for patients with mild to moderate COVID-19. Based on these results and data from other studies previously reviewed by the Panel, the Panel recommends against the use of ivermectin for the treatment of COVID-19.

For a full list of updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.